is retatrutide approved 2025 💊🔥 Retatrutide: The Most Powerful Weight-Loss Drug Yet? 🧬📊 New Phase 3 clinical results are turning heads retatrutide, a next-generation triple-agonist targeting GLP-1, GIP and glucagon receptors, showing unmatched levels of October 27, 2025: U.K. regulators

When I started losing weight, I encouraged a lot of my friends to think about doing a GLP-1

Below we survey other major moves and players in late 20232025 to put the Metsera deal in context

In recent years, compounding pharmacies have jumped into the market for blockbuster GLP-1 drugs

cardioprotective and neuroprotective findings come mainly from animal and in vitro/cell-based research, and evidence for bodybuilding-specific outcomes like added lean mass or strength in humans is limited or absent

doi: 10.1073/pnas.1212806109 62 TroutKKBasel-BrownLRickelsMRSchuttaMHPetrovaMFreemanEWet al

a 2025 systematic review noted critical safety data gaps)